Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® (iptacopan capsules) as ...

A combination treatment has shown promise for treating a rare blood disease, according to a clinical trial published in the journal Blood.

References 1. Risitano AM, Han B, Kulasekararaj AG, et al. Oral iptacopan monotherapy leads to long-term improvements in patient (Pt)-reported health-related quality of life (HRQoL) and ...

They are thus reported to be useful for the treatment of age-related macular degeneration, schizophrenia, atypical hemolytic uremic syndrome, membranous nephropathy, myasthenia gravis, paroxysmal ...